Drug Database
TH

thrombin (ThrombiRAAS)

✓ Approved

Shanghai RAAS Blood Products Co., Ltd. · F2 · 细胞治疗

什么是 thrombin?

thrombin 是一种细胞治疗,由Shanghai RAAS Blood Products Co., Ltd.研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名ThrombiRAAS
公司Shanghai RAAS Blood Products Co., Ltd.
药物类别细胞治疗
分子靶点F2
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

thrombin 作用于 1 个分子靶点:

F2coagulation factor II, thrombin (THPH1, PT)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

thrombin 针对 2 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Vascular disordersExtravasation blood✓ Approved
Vascular disordersHaemorrhage✓ Approved

相关研究文献

PubMedThrombosis journal2026-11-19

Concentration-dependent and platform-specific interference of argatroban and bivalirudin in routine coagulation assays.

Yan Jinghai J, Chen Wanjun W, Chen Weidong W, Yang Yongqiang Y et al.

Argatroban and bivalirudin may interfere with routine coagulation and antithrombin assays through direct thrombin inhibition. However, the magnitude of interference differs across analytical platforms owing to distinct assay principles and reagent formulations. This study aimed to characterize the specific impacts of argatroban and bivalirudin on results of routine coagulation and antithrombin tests on three widely utilized coagulation analytical platforms. Pooled normal human plasma was spiked with clinically relevant concentrations of argatroban (0-2.0 µg/mL) or bivalirudin (0-20 mg/L). Antithrombin (AT) activity, prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), and Clauss fibrinogen (FIB) were measured simultaneously on all three analytical platforms. Corresponding antigen concentrations of AT and ClaussFIB were quantified via immunoassays to discriminate analytical interference from genuine biological alterations. On Stago and Sysmex platforms, AT activity increased concentration‑dependently with both DTIs, whereas no significant change was observed on Werfen. Fibrinogen levels decreased markedly with argatroban only on Werfen, and with bivalirudin across all three platforms. PT, APTT, and TT were prolonged dose‑dependently on all platforms, though TT frequently exceeded the detection limit at low DTI concentrations. Inter‑platform agreement assessed by intraclass correlation coefficients was poor to moderate for most parameters. Antigen levels remained unchanged, confirming that the observed discrepancies were due to analytical interference. Argatroban and bivalirudin produce significant platform-dependent interference in coagulation testing, particularly in thrombin-based fibrinogen and AT activity assays. Such interference may lead to falsely decreased fibrinogen activity and falsely elevated AT activity. Platform-specific validation and confirmatory testing are essential for accurate interpretation of coagulation results during direct thrombin inhibitor therapy.

PMID 43053079
阅读全文 →
PubMedMediterranean journal of hematology and infectious diseases2026-11-18

Corrigendum to "Baseline Thrombin Generation Test Does Not Predict Thrombotic Events in Acute Leukemia: A Monocentric Prospective Study", Mediterr J Hematol Infect Dis 2025; 17(1): e2025076. DOI: 10.4084/MJHID.2025.076.

Biglietto M M, Mormile R R, Bisegna M L ML, Laganà A A et al.

[This corrects the article DOI: 10.4084/MJHID.2025.076.].

PMID 43048650
阅读全文 →
PubMedExpert review of hematology2026-11-18

Challenges in monitoring factor VIII activity during hemophilia a treatment: toward individualized monitoring strategies.

Nakajima Yuto Y, Nogami Keiji K

Factor VIII (FVIII) activity remains essential for diagnosing and classifying hemophilia A, conducting pharmacokinetic assessments, guiding perioperative management, and monitoring treatment. However, extended half-life FVIII products, emicizumab, and recently approved and emerging non-factor therapies have revealed important limitations of conventional FVIII activity assays. We conducted a targeted, non-systematic literature search using PubMed/MEDLINE, focusing primarily on publications from 1 September 2011, to 31 August 2026, supplemented by earlier seminal studies and reference-list screening. This review examines the current role and limitations of FVIII activity monitoring, including one-stage clotting and chromogenic assays, assay discrepancies in non-severe hemophilia A, monitoring of standard and extended half-life FVIII products, and laboratory assessment during emicizumab and other non-factor therapies. It also evaluates the potential complementary roles of global coagulation assays, including thrombin generation, clot waveform analysis, and viscoelastic testing. No single assay addresses every clinical question in contemporary hemophilia A care; FVIII activity measurement remains indispensable, but results must be interpreted according to the treatment, assay principle, reagent system, sampling time, and clinical purpose. An optimal strategy will combine validated FVIII assays with selected global coagulation assays when appropriate, although further standardization and clinical validation are required.

PMID 43052021
阅读全文 →
PubMedAdvanced healthcare materials2026-11-18

A Stearyl-Peptide Based Versatile Strategy to Design Enzyme-Responsive Liposomes for Targeted Drug Delivery.

Raghunathan Shruti S, Luc Norman N, Disharoon Dante D, Rohiwal Sonali S et al.

Liposomes are a prominent class of drug delivery nanoparticles. For currently approved liposomal therapeutics, drug is released predominantly via diffusion which has spatio-temporal kinetic and bioavailability challenges, especially in a dynamic environment. Next-generation liposome designs focus on stimuli-triggered enhancement of drug release. One exciting approach here is liposomes that can be site-specifically destabilized by disease-associated enzymes. Feasibility of this has been demonstrated with certain phospholipases or metalloproteases, but a versatile strategy for designing liposomes triggerable by any disease-specific enzyme remains lacking. We report a unique liposome design using enzyme-cleavable stearyl-peptide conjugates. Stearylamine has been explored for cationic liposomes in gene delivery, but the cationic charge poses significant cytotoxicity. We demonstrate that conjugating enzyme-cleavable peptides to stearylamine and assembly of stearyl-peptide conjugates within liposomes mitigates the cationic charge and significantly enhances biosafety. Surface-decorating such liposomes with target-specific ligands enables their active target-anchorage under flow. Exposure of target-anchored liposomes to disease-relevant enzymes renders stearyl-peptide cleavage and liposome destablization, enhancing drug release. We demonstrate the design versatility utilizing microfluidic models of three different vascular pathologies (hyperfibrinolysis, thrombosis and thromboinflammation) and delivering three corresponding drugs (tranexamic acid, tissue plasminogen activator and deoxyribonulease) triggered by three different enzymes (plasmin, thrombin and neutrophil elastase), respectively.

PMID 43046117
阅读全文 →
PubMedEuropean journal of haematology2026-11-18

Bleeding Symptoms, Laboratory, and Molecular Genetic Results in Children With Platelet Disorders.

Huisman Elise J EJ, Atiq Ferdows F, Veen Caroline S B CSB, van de Watering Leo L et al.

Diagnosing and classifying platelet disorders (PD) is challenging in children. Therefore, we evaluated clinical, laboratory, and genetic data to improve current algorithms by performing a prospective observational cohort study in children (0-18 years) with a known genetic cause (proven PD), functional abnormalities, or thrombocytopenia without genetic cause (probable PD) or medical suspicion of PD (possible PD). We included 98 children (mean age 11.6 years, 55 females). PD was proven in 44, probable in 43, and possible in 11. Comorbidities were present in 43. Epistaxis, hematomas, menstrual, and perioperative bleeding were reported most frequently. Mean ISTH-BAT bleeding score was 6.1 (SD 4.0, range 0-17), with higher scores in post-pubertal females (mean 7.6) and lower scores in children with moderate thrombocytopenia (mean 4.8). Bleeding as a presenting symptom and older age were associated with higher bleeding scores. Treatment was indicated in 46 children. Most frequently, Light transmission aggregometry was abnormal for ADP, epinephrine, and thrombin. General laboratory parameters can hint to but not identify PD origin. Genetic testing led to novel diagnoses in 10 (23%) children with probable PD. We conclude that bleeding tendency is prominent but variable in children with PD. Routine laboratory tests are useful, but fail to diagnose the origin of PD. Therefore, genetic analysis is essential, especially as PD can be part of a syndrome leading to comorbidities or predispose for malignancies, both impacting counseling and surveillance. We propose a classification based on functional and genetic analysis leading to either an isolated or syndrome-associated inherited PD or a functional PD. Trial Registration: ABR NL55101.078.16.

PMID 43046503
阅读全文 →
PubMedWorld journal of microbiology & biotechnology2026-11-18

Genomic insights into the probiotic safety, butyrate production, and type-II L-Asparaginase of Bacillus altitudinis AHK-Y5.

Naz Shahida S, Hasan Khwaja Ali KA, Bux Khair K, Hasan Khwaja Sulaeman KS et al.

Bacillus altitudinis is a resilient, spore-forming, Gram-positive bacterium. It thrives in soil, water, air, plant roots, and the human gut. It is a potential candidate for various industrial, biomedical, and biotechnological applications. This study analyzes an airborne B. altitudinis strain, AHK-Y5 for genome-based safety assessment (GBSA), and production and in silico analysis of L-asparaginase. The genome has 3.7 million base pairs and 3,822 genes. It lacks virulence and drug resistance genes and does not hold pathogenicity. It reveals genes that digest carbohydrates, produce short-chain fatty acids, vitamins, bacteriocins, and aid colonization. Metabolic analysis links B. altitudinis AHK-Y5 to probiotic strains like Bacillus subtilis 168 and Bacillus clausii KSM-K16. B. altitudinis AHK-Y5 produces a type-II L-asparaginase (BaltASNase) which is encoded by the ansZ gene and has a Km of 7.47 µM and a Vmax of 30.30 µM/min, making it a great fit for medical and industrial uses. In silico analysis predicted an extended half-life, high solubility, low hydrophobicity, favorable immunogenicity despite low antigenic potency, and stability against serine proteases such as thrombin and factor Xa. Molecular docking shows it binds best to L-asparagine with a high energy of -4.92 Kcal/mol and a 1.08 Å RMSD compared to D-asparagine, bis-acrylamide and L-lysine. In conclusion, Bacillus altitudinis AHK-Y5 lacks genes for toxins, virulence, or transmissible antibiotic resistance. Genomic analysis identified the strain as a type-II L-asparaginase producer and revealed probiotic potential through genes linked to acid and bile tolerance, adhesion, and vitamin biosynthesis; however, experimental validation is required.

PMID 43049972
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多thrombin